Article
Medicine, General & Internal
Y. Doki, J. A. Ajani, K. Kato, J. Xu, L. Wyrwicz, S. Motoyama, T. Ogata, H. Kawakami, C. -H. Hsu, A. Adenis, F. El Hajbi, M. Di Bartolomeo, M. I. Braghiroli, E. Holtved, S. A. Ostoich, H. R. Kim, M. Ueno, W. Mansoor, W. -C. Yang, T. Liu, J. Bridgewater, T. Makino, I. Xynos, X. Liu, M. Lei, K. Kondo, A. Patel, J. Gricar, I. Chau, Y. Kitagawa
Summary: In patients with advanced esophageal squamous-cell carcinoma, both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone, with no new safety signals identified.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Genetics & Heredity
Adam N. Bennett, Rui Xuan Huang, Qian He, Nikki P. Lee, Wing-Kin Sung, Kei Hang Katie Chan
Summary: Esophageal cancer, particularly esophageal squamous cell carcinoma, is a significant challenge globally, with high incidence and mortality rates. The limited number of effective therapeutic options contributes to the high mortality rate. Repurposing existing drugs approved for other diseases through drug repositioning is a more time and cost-effective strategy. This study identified potential therapeutic drugs for esophageal cancer patients through gene expression analysis and network analysis, including both known drugs like Doxorubicin and potential psychiatric drugs like Venlafaxine.
FRONTIERS IN GENETICS
(2022)
Article
Biochemistry & Molecular Biology
Jinsei Miyoshi, Zhongxu Zhu, Aiping Luo, Shusuke Toden, Xuantong Zhou, Daisuke Izumi, Mitsuro Kanda, Tetsuji Takayama, Iqbal M. Parker, Minjie Wang, Feng Gao, Ali H. Zaidi, Hideo Baba, Yasuhiro Kodera, Yongping Cui, Xin Wang, Zhihua Liu, Ajay Goel
Summary: In this study, a circulating microRNA signature for early detection of esophageal squamous cell carcinoma (ESCC) was established and validated in multiple cohorts. The signature showed superior diagnostic performance compared to current clinical serological markers.
Article
Nutrition & Dietetics
Shanshan Li, Joshua Ye, Zheng Lin, Zhifeng Lin, Xuwei Tang, Wenqing Rao, Zhijian Hu
Summary: This study investigated the independent and interactive effects of dietary nutrients on the risk of Esophageal Squamous Cell Carcinoma (ESCC) in Chinese adults. The results showed that fat, carbohydrate, and fiber intake significantly increased ESCC risk, while fiber and riboflavin intake significantly reduced the risk.
Article
Oncology
Dongxian Jiang, Haixing Wang, Minying Deng, Qi Song, Yufeng Liu, Rui Peng, Lei Xu, Jieakesu Su, Chen Xu, Yingyong Hou
Summary: The number of diagnosed esophageal basaloid squamous cell carcinoma (EBSCC) has been increasing recently, but available data on EBSCC are limited. A retrospective analysis of 165 EBSCC and 515 conventional esophageal squamous cell carcinoma (ESCC) showed that EBSCC had similar prognosis to ESCC in pIA-B stage, pIIA-B stage, pIIIA-B stage, and pIVA-B stage. Pure EBSCC did not have poorer survival compared to mixed EBSCC with concomitant ESCC or other components.
Article
Cell Biology
Weixiong Yang, Chang-Han Chen, Minghan Jia, Xiangbin Xing, Lu Gao, Hsin-Ting Tsai, Zhanfei Zhang, Zhenguo Liu, Bo Zeng, Sai-Ching Jim Yeung, Mong-Hong Lee, Chao Cheng
Summary: The study revealed significant differences in the microbiota composition between patients with ESCC and those with PN esophagus, with the former showing reduced microbial diversity and decreased abundances of specific taxa. Functional analysis indicated altered nitrate reductase and nitrite reductase functions in the microbiota of ESCC patients. These findings suggest that specific microbes and microbiota may influence the development of ESCC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Qingfu Zhu, Liu Huang, Qinsi Yang, Zheng Ao, Rui Yang, Jonathan Krzesniak, Doudou Lou, Liang Hu, Xiaodan Dai, Feng Guo, Fei Liu
Summary: Metabolomic analysis of plasma exosomes in patients with ESCC revealed 196 metabolites, with a marker set of 3'-UMP, palmitoleic acid, palmitaldehyde, and isobutyl decanoate showing high accuracy in predicting ESCC recurrence. These exosome metabolome signatures, likely associated with cancer metabolism, could potentially serve as novel biomarkers for diagnosis and prognosis of ESCC.
Article
Oncology
Yasukazu Kanie, Akihiko Okamura, Suguru Maruyama, Kei Sakamoto, Daisuke Fujiwara, Jun Kanamori, Yu Imamura, Masayuki Watanabe
Summary: This study retrospectively analyzed 208 patients with recurrent ESCC after surgery and found that elevated serum SCC-Ag levels at recurrence were significantly associated with a reduced time to recurrence, multiple recurrences, and a poor prognosis after recurrence. Further research is needed to find alternative treatments for patients with high serum SCC-Ag levels at recurrence.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Long Zhang, Jinchen Shao, Zhichao Liu, Jie Pan, Bin Li, Yang Yang, Yi He, Yuchen Han, Zhigang Li
Summary: PNI is associated with lymphovascular invasion and advanced tumor invasion in ESCC patients, and although not an independent prognostic indicator, patients with PNI positivity should be considered for adjuvant therapy.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Zheng Lin, Wenqing Rao, Zhisheng Xiang, Qiaoyan Zeng, Shuang Liu, Kaili Yu, Jinsong Zhou, Jianwen Wang, Weilin Chen, Yuanmei Chen, Xiane Peng, Zhijian Hu
Summary: The diversity and composition of microbial communities in esophageal tumor tissues were found to be significantly different from tumor-adjacent tissues in patients with esophageal squamous cell carcinoma (ESCC). Certain microbial species were associated with ESCC and were found to be linked to signaling pathways involved in cancer development and progression. These findings suggest that alterations in the esophageal microbiota may play a role in the pathobiology of ESCC.
Article
Medicine, General & Internal
Sora Kim, Gwang Ha Kim, Su Jin Park, Chae Hwa Kwon, I Hoseok, Moon Won Lee, Bong Eun Lee
Summary: Exosomal miRNAs have the potential to serve as biomarkers for esophageal squamous cell carcinoma (ESCC). This study identified specific exosomal miRNAs that were differentially expressed in ESCC, and validated their expression levels in the plasma of healthy controls and ESCC patients. The results showed that plasma exosomal miR-205-5p, miR-429, and miR-375-3p could be potential biomarkers for the diagnosis of ESCC.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Yuxian Yang, Shiliang Liu, Chunxia Xie, Qiaoqiao Li, Tiantian Gao, Mengzhong Liu, Mian Xi, Lei Zhao
Summary: This study revealed the oncogenic role of TMED3 in esophageal squamous cell carcinoma (ESCC) and identified the overexpression of a TMED3-related protein FAM60A in ESCC tissues. Functional verification experiments demonstrated the important roles of TMED3 and FAM60A in ESCC cell proliferation and tumorigenicity.
BIOMEDICAL JOURNAL
(2023)
Review
Medicine, Research & Experimental
Tao Yang, Ruting Hui, Jessica Nouws, Maor Sauler, Tianyang Zeng, Qingchen Wu
Summary: This study identified that glycerophospholipid metabolism is associated with the tumorigenesis and progression of esophageal squamous cell carcinoma (ESCC), and could be a potential therapeutic target for ESCC progression.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Chemistry, Physical
Yida Huang, Haijun Yang, Junkuo Li, Fuqiang Wang, Wanshan Liu, Yiwen Liu, Ruimin Wang, Lijuan Duan, Jiao Wu, Zhaowei Gao, Jing Cao, Fang Bian, Juxiang Zhang, Fang Zhao, Shouzhi Yang, Shasha Cao, Aihua Yang, Xueliang Wang, Mingfei Geng, Anlin Hao, Jian Li, Jianwei Cao, Chaowei Li, Zheyuan Zhang, Ning Zhang, Yanlin Huang, Yaowen Zhang, Kun Qian, Fuyou Zhou
Summary: In this study, ferric-particle-enhanced laser desorption/ionization mass spectrometry was used to record the serum metabolic fingerprints and build diagnostic models for ESCC. A metabolic biomarker panel was constructed with high diagnostic sensitivity for early ESCC.
Article
Immunology
Zhi Zhang, Jinjun Ye, Hui Li, Dayong Gu, Mingyu Du, Dashan Ai, Wei Chen, Ying Fang, Xinyu Xu, Chenguang Bai, Kuaile Zhao, Guoren Zhou
Summary: This study evaluated the activity and safety of neoadjuvant sintilimab combined with chemotherapy in the treatment of resectable esophageal squamous cell carcinoma (ESCC). The results showed a relatively high pathological complete response (PCR) rate and acceptable safety, suggesting that this combination therapy warrants further investigation in resectable ESCC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Pharmacology & Pharmacy
Go Ikeda, Shun Yamamoto, Ken Kato
Summary: For advanced esophageal cancer patients, the combination of platinum and fluoropyrimidine is the standard first-line treatment, while taxane or irinotecan may be used after first-line treatment. Immune checkpoint inhibitors like pembrolizumab and nivolumab have shown potential to prolong survival as second-line treatments. Regular monitoring for immune-related adverse events and individualized supportive care may be necessary. Immune-related toxicities should be carefully considered when using ICIs in different treatment settings.
EXPERT OPINION ON DRUG SAFETY
(2022)
Article
Oncology
Kotoe Oshima, Ken Kato, Yoshinori Ito, Hiroyuki Daiko, Isao Nozaki, Satoru Nakagawa, Yuichi Shibuya, Takashi Kojima, Yasushi Toh, Morihito Okada, Shuichi Hironaka, Yuji Akiyama, Yoshito Komatsu, Kazuhiro Maejima, Hidewaki Nakagawa, Ritsuko Onuki, Momoko Nagai, Mamoru Kato, Keisuke Kanato, Aya Kuchiba, Kenichi Nakamura, Yuko Kitagawa
Summary: Genomic analyses of Japanese patients with stage I esophageal squamous cell carcinoma (ESCC) revealed associations between genomic alterations and survival outcomes. Specifically, genomic alterations in FGF19 were strongly associated with progression-free survival. These findings have implications for the development of new treatments for ESCC patients.
Letter
Gastroenterology & Hepatology
Ken Kato, Tomohiro Kadota, Seiichiro Abe
Article
Oncology
Morihito Okada, Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, Chueh-Chuan Yen, Yutaro Kubota, Sung-Bae Kim, Chih-Hung Hsu, Eva Holtved, Ioannis Xynos, Yasuhiro Matsumura, Akira Takazawa, Yuko Kitagawa
Summary: This study reports 3-year follow-up data comparing nivolumab with chemotherapy in previously treated advanced esophageal squamous cell carcinoma patients, showing that nivolumab demonstrated clinically meaningful long-term improvement in overall survival compared with chemotherapy, regardless of the best overall response.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Kentaro Harada, Shun Yamamoto, Ken Kato
Summary: The prognosis of advanced esophageal cancer remains poor, with limited effective treatment options. Pembrolizumab monotherapy has shown benefits for patients with advanced esophageal squamous cell carcinoma who have a combined positive score of >=10. Additionally, pembrolizumab plus chemotherapy as first-line treatment provides significant survival benefits compared to chemotherapy alone.
Article
Oncology
Lin Shen, Ken Kato, Sung-Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Longzhen Zhang, Tienan Yi, Jong-Mu Sun, Jianhua Chen, Guohua Yu, Chen-Yuan Lin, Hiroki Hara, Qing Bi, Taroh Satoh, Roberto Pazo-Cid, Hendrick-Tobias Arkenau, Christophe Borg, Florian Lordick, Liyun Li, Ningning Ding, Aiyang Tao, Jingwen Shi, Eric Van Cutsem
Summary: Tislelizumab significantly improves overall survival in patients with advanced or metastatic ESCC, and has a tolerable safety profile. Patients with TAP >= 10% also demonstrate significant survival benefit with tislelizumab compared to chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Hanae Ida, Takafumi Koyama, Takaaki Mizuno, Kuniko Sunami, Takashi Kubo, Kazuki Sudo, Kayoko Tao, Makoto Hirata, Kan Yonemori, Ken Kato, Takuji Okusaka, Yuichiro Ohe, Yoshiyuki Matsui, Naoya Yamazaki, Chitose Ogawa, Akira Kawai, Yoshitaka Narita, Minoru Esaki, Noboru Yamamoto
Summary: This study assessed the clinical utility of comprehensive genomic profiling (CGP) tests in advanced or metastatic solid tumor patients, and found that the proportion of patients receiving genomically matched therapy was significantly higher among those with common cancers than non-common cancers.
Article
Gastroenterology & Hepatology
Ken Kato, Yuichiro Doki, Takashi Ogata, Satoru Motoyama, Hisato Kawakami, Masaki Ueno, Takashi Kojima, Yasuhiro Shirakawa, Morihito Okada, Ryu Ishihara, Yutaro Kubota, Carlos Amaya-Chanaga, Tian Chen, Yasuhiro Matsumura, Yuko Kitagawa
Summary: The results of the Japanese subpopulation of CheckMate 648 show that first-line treatment with nivolumab plus ipilimumab or nivolumab plus chemotherapy significantly prolongs survival in advanced esophageal squamous cell carcinoma patients, with acceptable tolerability.
Review
Gastroenterology & Hepatology
Toshiharu Hirose, Shun Yamamoto, Ken Kato
Summary: Esophageal cancer is the seventh most common malignancy worldwide. Pembrolizumab has shown significant overall survival benefit as a first-line treatment for advanced esophageal squamous cell carcinoma. It is now considered the standard treatment for advanced esophageal cancer.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Oncology
Juntaro Matsuzaki, Ken Kato, Kenta Oono, Naoto Tsuchiya, Kazuki Sudo, Akihiko Shimomura, Kenji Tamura, Sho Shiino, Takayuki Kinoshita, Hiroyuki Daiko, Takeyuki Wada, Hitoshi Katai, Hiroki Ochiai, Yukihide Kanemitsu, Hiroyuki Takamaru, Seiichiro Abe, Yutaka Saito, Narikazu Boku, Shunsuke Kondo, Hideki Ueno, Takuji Okusaka, Kazuaki Shimada, Yuichiro Ohe, Keisuke Asakura, Yukihiro Yoshida, Shun-Ichi Watanabe, Naofumi Asano, Akira Kawai, Makoto Ohno, Yoshitaka Narita, Mitsuya Ishikawa, Tomoyasu Kato, Hiroyuki Fujimoto, Shumpei Niida, Hiromi Sakamoto, Satoko Takizawa, Takuya Akiba, Daisuke Okanohara, Kouya Shiraishi, Takashi Kohno, Fumitaka Takeshita, Hitoshi Nakagama, Nobuyuki Ota, Takahiro Ochiya
Summary: This study demonstrates that large-scale serum miRNomics in combination with machine learning could lead to the development of a blood-based cancer classification system, providing a promising method for noninvasive detection of early-stage cancers.
JNCI CANCER SPECTRUM
(2023)
Review
Oncology
Yuntae Kim, Shun Yamamoto, Ken Kato
Summary: Esophageal cancer is a common malignancy, with esophageal squamous cell carcinoma being the predominant subtype. Effective treatment options for patients with this subtype are limited. The use of immunotherapy, specifically nivolumab, has shown promising results in the treatment of metastatic esophageal cancer. This review discusses the efficacy and safety of postoperative nivolumab and explores the potential use of immune checkpoint inhibitors in the perioperative therapy of locally advanced esophageal squamous cell carcinoma.
CANCER MANAGEMENT AND RESEARCH
(2023)
Review
Oncology
Yuri Yoshinami, Erica Nishimura, Taisuke Hosokai, Shun Yamamoto, Satoru Matsuda, Motoo Nomura, Hirofumi Kawakubo, Ken Kato, Yuko Kitagawa
Summary: Esophageal cancer is a common disease worldwide with various histological subtypes. Rare esophageal cancers, such as neuroendocrine neoplasm and gastrointestinal stromal tumor, have different treatment strategies due to their distinct biological features. Limited evidence is available for these rare cancers. Neuroendocrine neoplasm, gastrointestinal stromal tumor, carcinosarcoma, and malignant melanoma each require specific treatment approaches. Primary malignant melanoma of the esophagus is resistant to cytotoxic chemotherapy but may respond to immune checkpoint inhibitors.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Yuta Ueno, Emiko Yoshida, Shuko Nojiri, Tomoyasu Kato, Takashi Ohtsu, Toshiyuki Takeshita, Shunji Suzuki, Hiroshi Yoshida, Ken Kato, Masayoshi Itoh, Tsuguto Notomi, Kengo Usui, Takashi Sozu, Yasuhisa Terao, Hideya Kawaji, Hisamori Kato
Summary: This study examined the association between 18 preoperative clinical variables and lymph node metastasis in endometrial cancer and developed a statistical model for prediction. The results showed that the new predictive model outperformed the previous method in predicting lymph node metastasis.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Keita Sasaki, Motoo Nomura, Ken Kato, Katsuyuki Sakanaka, Yoshinori Ito, Tomohiro Kadota, Ryunosuke Machida, Tomoko Kataoka, Keiko Minashi, Yasuhiro Tsubosa, Takeshi Kajiwara, Haruhiko Fukuda, Hiroya Takeuchi, Takashi Mizowaki, Yasumasa Nishimura, Yuko Kitagawa, Japan Esophageal Oncology Grp, Radiation Therapy Study Grp, Japan Clinical Oncology Grp
Summary: Chemoradiotherapy with elective nodal irradiation has been reported to reduce the locoregional recurrence of esophageal squamous cell carcinoma. This clinical trial aims to confirm the superiority of modified chemoradiotherapy with elective nodal irradiation compared to that without elective nodal irradiation for T1bN0M0 esophageal squamous cell carcinoma.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Yasuo Hamamoto, Kentaro Murakami, Ken Kato, Yuko Kitagawa
Summary: This review focuses on the treatment of elderly esophageal cancer and clarifies the current situation. The review highlights the fundamental differences between Japan and the rest of the world in terms of histological differences and treatment strategies for resectable patients. The authors also discuss the lack of established evaluation criteria for frailty, the absence of selection criteria for surgery or non-surgery, and the limited research on specific treatments for elderly patients. Overall, there are many reports on the treatment of esophageal squamous cell carcinoma in elderly patients, although the optimal treatment strategy remains controversial.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2022)